Opening the book…
FDA has legal authority to inspect covered pharmaceutical establishments and examine relevant records. Inspections may evaluate whether a facility follows cGMP and whether its systems consistently produce products that meet requirements. Manufacturers should maintain readiness through routine quality practices rather than preparing only when an inspection is expected.
Inspection coverage depends on the product, facility, and risks. For example, an inspector may examine a pharmaceutical water system, equipment cleaning, laboratory controls, deviation investigations, supplier qualification, and batch release decisions. Guidance and inspection manuals help explain FDA approaches but do not replace applicable law. 
A drug can be legally adulterated because its manufacturing methods, facilities, or controls fail to meet cGMP requirements even without a demonstrated defect in a tested batch. Depending on the circumstances, enforcement can include court-ordered corrective actions, restrictions on manufacturing or distribution, and criminal proceedings pursued through the Department of Justice.
At the end of an inspection, investigators may issue Form FDA 483, Inspectional Observations, when they observe conditions that may violate the laws FDA administers. The form communicates significant observations to facility management; it is not a final agency determination of compliance.
A warning letter is a separate advisory action describing violations FDA has identified and requesting corrective action. It may follow an inspection or other evidence. A Form 483 does not automatically lead to a warning letter, and a warning letter is not required before every enforcement action.
FDA may also issue public communications or recommend legal action. Court proceedings, including injunctions, seizures, and criminal prosecutions, involve the Department of Justice and the courts. Serious or persistent problems may justify action without a fixed sequence of warnings.
FDA recommends a written response to Form 483 observations within 15 business days. A useful response addresses the investigation, root cause, immediate corrections, corrective and preventive actions (CAPA), supporting evidence, and realistic completion dates. This response period is not a grace period that prevents enforcement or a requirement to finish every complex correction in 15 days. Follow the specific instructions in any FDA correspondence.
A strong investigation response connects a finding to evidence, actions, responsibilities, and follow-up. Immediate correction addresses the problem at hand. Corrective action addresses a supported cause so the problem is less likely to recur. Broader preventive work may address similar vulnerabilities in other processes or sites.
Effectiveness checks ask whether the action achieved its purpose. Counting how many employees attended retraining may show completion of training but not improved performance. Reviewing later records, observing practice, and monitoring repeat events can provide more direct evidence. Measures and follow-up timing should fit the problem and risks.
A consent decree is a court-entered agreement resolving a legal action. In an FDA enforcement case, the United States and the defendants agree to terms that a federal court approves and enforces. The decree may require corrective work, independent expert review, reporting, or restrictions on operations. It is not simply a notice issued by FDA after a fixed number of inspection findings.
Terms vary by case and may include reimbursement of inspection costs, deadlines, and penalties for noncompliance. Operations may be restricted until specified conditions are met. Changes to, or termination of, a decree depend on its terms and the court; compliance does not automatically end the order.
This page titled 12.7: Inspections and Enforcement was last modified on Sun, 08 Nov 2026 15:03:40 GMT and is shared under a CC BY-SA 4.0 license and was authored, remixed, and/or curated by .
The book could not be loaded just now.